BioSpace News Archive

TOTUM-070 is being developed particularly for individuals with untreated hypercholesterolemia, with LDL-cholesterol levels up to 190 mg/dL associated with moderate overall cardiovascular risk. It responds to an unmet medical need for this population; TOTUM-070 has high potential in the market for non-drug LDL-cholesterol products, which is estimated at 1.2 billion euros (USA + top 5 Europe) 1 ; The clinical study HEART on TOTUM-070, a Phase II

POXEL SA (Euronext: POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced that members of the Poxel management and scientific team will participate at several upcoming scientific and investor conferences. B. Riley Liver Disease Therapeutics Day Date: October

Bayer announced its plans to build a new 220,000 sq. ft. Distribution Center to support the ongoing growth of Bayer’s Radiology global business that supplies medical device products world-wide.

Intermountain Healthcare and Intermountain Primary Children’s Hospital are launching a bold plan to enhance mental and behavioral health services for children and teens in crisis throughout the Intermountain West – an effort that has inspired an extraordinary $10 million gift from Utah community leaders Greg and Julie Cook. The Cooks’ generous and transformational gift to the Intermountain Foundation will help Intermountain Healthcare

Global heart health leader implores U.S. adults to monitor their blood pressure weekly and take action if they are among the 116 million Americans in the hypertensive range

Biocom Purchasing Group, a subsidiary of Biocom that accelerates life science success by leveraging innovative, member-driven strategic sourcing solutions that significantly lower the total cost of doing business, today announced a new program with Everlywell to offer at-home sample coll

Q3 2020 net sales exceed outlook with 26% CER increase and adjusted diluted EPS grows 61% to $0.58 CER, hits high end of outlook range Full-year 2020 outlook raised to ~20% CER net sales growth and ~$2.07-2.09 CER adjusted EPS QIAGEN Virtual Deep Dive investor event planned for December 8, 2020

QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced it would hold a conference call on Wednesday, October 28, after releasing full results for the third quarter and first nine months of 2020 on Tuesday, October 27. The call is scheduled for 14:00 Frankfurt time / 13:00 London time / 9:00 New York time. It will be hosted by Thierry Bernard, Chief Executive Officer, and Roland Sackers, Ch

Unprecedented clinical study results presented at Infectious Diseases Society of America (IDSA) Annual Conference, IDWeek 2020

Two Japanese institutions, a Korean biotechnology start-up, and a Canadian biotech company have entered into a research collaboration to identify biomarkers unique to lung cancer cells suitable for targeted therapeutics.